Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Relaxes AAA Panel Meeting Criteria; Thoracic Endograft Approvals Lag

This article was originally published in The Gray Sheet

Executive Summary

Abdominal aortic aneurysm endograft applications will no longer require advisory panel review, unless new issues arise in the course of FDA's premarket evaluation
Advertisement

Related Content

Gore’s TAG Thoracic Endograft Is First To Go Before FDA Panel
Gore’s TAG Thoracic Endograft Is First To Go Before FDA Panel
AAA Workshop Participants De-Emphasize Preclinical Animal Studies
AAA Workshop Participants De-Emphasize Preclinical Animal Studies
Cook Zenith TX2 Thoracic Aortic Aneurysm Graft On Track For 2006 Launch
Guidant Agrees With OIG To Educate Employees, Promote Reporting
Guidant Agrees With OIG To Educate Employees, Promote Reporting
AAA Graft Pre-Clinical Workshop Input Could Be Included In ISO Standards
Advertisement
UsernamePublicRestriction

Register

MT020229

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel